TNF Pharmaceuticals, Inc. financial data

Symbol
TNFA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
855 N. Wolfe Street, Suite 601, Baltimore, MD
State of incorporation
Delaware
Fiscal year end
December 31
Former names
MyMD Pharmaceuticals, Inc. (to 7/1/2024), Akers Biosciences, Inc. (to 4/16/2021), Akers Biosciences Inc (to 4/11/2017)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 158 % -68.2%
Debt-to-equity 108 % +87.2%
Return On Equity -187 % -102%
Return On Assets -87.8 % -53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.37M shares -95.3%
Common Stock, Shares, Outstanding 2.37M shares -94.4%
Entity Public Float 63M USD -10.4%
Common Stock, Value, Issued 112M USD +3.92%
Weighted Average Number of Shares Outstanding, Basic 2.28M shares +61.3%
Weighted Average Number of Shares Outstanding, Diluted 2.28M shares +61.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.47M USD -10.9%
General and Administrative Expense 4.66M USD -17.4%
Operating Income (Loss) -14.9M USD +6.2%
Nonoperating Income (Expense) -2.78M USD -200%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.7M USD -34.8%
Net Income (Loss) Attributable to Parent -17.7M USD -34.8%
Earnings Per Share, Basic -10.6 USD/shares +33.6%
Earnings Per Share, Diluted -10.6 USD/shares -41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 536K USD +471%
Marketable Securities, Current 12.5M USD +8.64%
Assets, Current 14.4M USD +9.24%
Operating Lease, Right-of-Use Asset 25.8K USD -76%
Goodwill 10.5M USD 0%
Assets 26.4M USD +4.49%
Accounts Payable, Current 4.62M USD +114%
Accrued Liabilities, Current 524K USD +5.41%
Liabilities, Current 5.78M USD +138%
Operating Lease, Liability, Noncurrent 20.5K USD -78%
Liabilities 26M USD +89.1%
Retained Earnings (Accumulated Deficit) -123M USD -23.4%
Stockholders' Equity Attributable to Parent 97.8K USD -99.1%
Liabilities and Equity 26.4M USD +4.49%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.91M USD +51.9%
Net Cash Provided by (Used in) Financing Activities -1.28M USD -109%
Net Cash Provided by (Used in) Investing Activities 732K USD
Common Stock, Shares Authorized 250M shares -50%
Common Stock, Shares, Issued 2.37M shares -94.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.46M USD -338%
Deferred Tax Assets, Valuation Allowance 30.1M USD -12.1%
Operating Lease, Liability 25.8K USD -76.5%
Lessee, Operating Lease, Liability, to be Paid 27K USD -77.3%
Operating Lease, Liability, Current 25.8K USD -63.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 16.2K USD -78.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.2K USD -86.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.81K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +1.22%
Preferred Stock, Shares Authorized 50M shares 0%
Operating Lease, Payments 9.34K USD -48.8%
Additional Paid in Capital 123M USD
Share-based Payment Arrangement, Expense 299K USD +1401%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares